Approximately 80% of people in India are affected by acne between the onset of puberty and 30 years of age. It is estimated that by the end of 2026 the number of people affected by acne will reach around 23 million at a compound annual growth rate. Acne vulgaris is one of the most common diseases affecting humanity and its impact on quality of life is important. Mumbai (India)-based, Glenmark Pharmaceuticals has taken note of this problem and has lately developed MINYM which is India’s first topical Minocycline 4% gel for the treatment of moderate to severe acne. MINYM gel has been developed to address the rising issues in the treatment of acne and the USP of this product lies in the fact that it can be used in patients above the age of 9 years.
This is an effective antimicrobial gel which has anti-inflammatory properties and also has the lowest MIC9O which implies (minimal inhibitory concentration at which it stops or prevents visible growth of 90% of bacteria isolates) among available topical antibacterial formulations in the Indian market today. The inspiration for the launch of MINYM lies in a study conducted by Glenmark in 2020 on the prevalence of acne in India. The study showed that more than 72% of the patients were in the adolescent group and 27% were in the adult group. It was observed that 45% of the patients were males and 55% patients were females.